Lipid and lipoprotein dysregulation in insulin resistant states

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 1-19

  Avramoglu, Rita Kohen ^a   Basciano, Heather ^a   Adeli, Khosrow ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Insulin resistant states; Lipid; Lipoprotein dysregulation

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; MEMBRANE PROTEIN; PHOSPHATASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TRIGLYCERIDE TRANSFER PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ATHEROGENESIS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DOWN REGULATION; DYSLIPIDEMIA; GLUCOGENESIS; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DIET; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS;

EID: 33646826006     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.026     Document Type: Review

References (252)

1. Mackay J., and Mensah G.A. The atlas of heart disease and stroke (2004)
2. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
3. Hogan P., Dall T., and Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
4. Glaser N.S., and Jones K.L. Non-insulin dependent diabetes mellitus in Mexican-American children. West J Med 168 (1998) 11-16
5. Grandinetti A., Chang H.K., Mau M.K., et al. Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project. Diabetes Care 21 (1998) 549-554
6. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl 5 (1997) S1-S85
7. Pan X.R., Yang W.Y., Li G.W., and Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 20 (1997) 1664-1669
8. Ramachandran A., Snehalatha C., Latha E., Vijay V., and Viswanathan M. Rising prevalence of NIDDM in an urban population in India. Diabetologia 40 (1997) 232-237
9. Dowse G., and Zimmet P. The thrifty genotype in non-insulin dependent diabetes. BMJ 306 (1993) 532-533
10. Collier G.R., De Silva A., Sanigorski A., Walder K., Yamamoto A., and Zimmet P. Development of obesity and insulin resistance in the Israeli sand rat (Psammomys obesus). Does leptin play a role?. Ann N Y Acad Sci 827 (1997) 50-63
11. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., and Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92 (1993) 141-146
12. Taskinen M.R. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 6 (1995) 153-160
13. Zimmet P.Z. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from West to the rest. Diabetes Care 15 (1992) 232-252
14. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
15. Pinhas-Hamiel O., Dolan L.M., Daniels S.R., Standiford D., Khoury P.R., and Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 128 (1996) 608-615
16. Sinha R., Fisch G., Teague B., et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346 (2002) 802-810
17. Bao W., Srinivasan S.R., and Berenson G.S. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study. Circulation 93 (1996) 54-59
18. Freedman D.S., Khan L.K., Dietz W.H., Srinivasan S.R., and Berenson G.S. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 108 (2001) 712-718
19. Kylin E. Studien über das Hypertoni-Hyperglykemi-Hyperurikemi syndrom. Zent.bl Inn Med 44 (1923) 105-112
20. Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesite. Presse Med 30 (1947) 339-340
21. Avogaro P., Crepaldi G., Enzi G., and Tiengo A. Metabolic aspects of essential obesity. Epatologia 11 (1965) 226-238
22. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149 (1989) 1514-1520
23. Ferrannini E., Haffner S.M., Mitchell B.D., and Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (1991) 416-422
24. Alberti K.G. Impaired glucose tolerance: what are the clinical implications?. Diabetes Res Clin Pract 40 Suppl (1998) S3-S8
25. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
26. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
27. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
28. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr Mol Med 5 (2005) 297-308
29. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
30. Haffner S.M., Alexander C.M., Cook T.J., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
31. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98 (1998) 2513-2519
32. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
33. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., and Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
34. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
35. Koskinen P., Manttari M., Manninen V., Huttunen J.K., Heinonen O.P., and Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
36. Robins S.J. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 88 (2001) 19N-23N
37. Robins S.J., Rubins H.B., Faas F.H., et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
38. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
39. Forster T. Milestone in the treatment of diabetic dyslipidemia: the DAIS Study. Orv Hetil 142 (2001) 1588-1589
40. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 39 (1996) 1655-1661
41. Florkowski C.M. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am J Cardiovasc Drugs 2 (2002) 15-21
42. Olansky L., Marchetti A., and Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 25 Suppl B (2003) B64-B80
43. Verges B. Clinical interest of PPARs ligands. Diabetes Metab 30 (2004) 7-12
44. Storlien L., Oakes N.D., and Kelley D.E. Metabolic flexibility. Proc Nutr Soc 63 (2004) 363-368
45. Uauy R., and Diaz E. Consequences of food energy excess and positive energy balance. Public Health Nutr 8 (2005) 1077-1099
46. Jenkins D.J., Wolever T.M., Taylor R.H., et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 34 (1981) 362-366
47. Jenkins D.J., and Jenkins A.L. The glycemic index, fiber, and the dietary treatment of hypertriglyceridemia and diabetes. J Am Coll Nutr 6 (1987) 11-17
48. Liu S., and Manson J.E. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. Curr Opin Lipidol 12 (2001) 395-404
49. Miller J.C. Importance of glycemic index in diabetes. Am J Clin Nutr 59 (1994) 747S-752S
50. Hwang I.S., Ho H., Hoffman B.B., and Reaven G.M. Fructose-induced insulin resistance and hypertension in rats. Hypertension 10 (1987) 512-516
51. Kasim-Karakas S.E., Vriend H., Almario R., Chow L.C., and Goodman M.N. Effects of dietary carbohydrates on glucose and lipid metabolism in golden Syrian hamsters. J Lab Clin Med 128 (1996) 208-213
52. Gross L.S., Li L., Ford E.S., and Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 79 (2004) 774-779
53. Bray G.A., Nielsen S.J., and Popkin B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79 (2004) 537-543
54. Levine R. Monosaccharides in health and disease. Annu Rev Nutr 6 (1986) 211-224
55. Ziegler O., Quilliot D., Guerci B., and Drouin P. Macronutrients, fat mass, fatty acid flux and insulin sensitivity. Diabetes Metab 27 (2001) 261-270
56. Kok N., Roberfroid M., and Delzenne N. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 45 (1996) 1547-1550
57. Bennett M.K., Lopez J.M., Sanchez H.B., and Osborne T.F. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J Biol Chem 270 (1995) 25578-25583
58. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
59. Foretz M., Guichard C., Ferre P., and Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A 96 (1999) 12737-12742
60. Guillet-Deniau I., Mieulet V., Le Lay S., et al. Sterol regulatory element binding protein-1c expression and action in rat muscles: insulin-like effects on the control of glycolytic and lipogenic enzymes and UCP3 gene expression. Diabetes 51 (2002) 1722-1728
61. Kim J.B., Sarraf P., Wright M., et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101 (1998) 1-9
62. Sewter C., Berger D., Considine R.V., et al. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 51 (2002) 1035-1041
63. Boizard M., Le L X., Lemarchand P., Foufelle F., Ferre P., and Dugail I. Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J Biol Chem 273 (1998) 29164-29171
64. Shimomura I., Bashmakov Y., and Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274 (1999) 30028-30032
65. Kazumi T., Vranic M., and Steiner G. Triglyceride kinetics: effects of dietary glucose, sucrose, or fructose alone or with hyperinsulinemia. Am J Physiol 250 (1986) E325-E330
66. Parks E.J., and Hellerstein M.K. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 71 (2000) 412-433
67. Fried S.K., and Rao S.P. Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 78 (2003) 873S-880S
68. Zammit V.A., Waterman I.J., Topping D., and McKay G. Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. J Nutr 131 (2001) 2074-2077
69. Knudsen P., Eriksson J., Lahdenpera S., Kahri J., Groop L., and Taskinen M.R. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group. Diabetologia 38 (1995) 344-350
70. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes Metab Rev 3 (1987) 551-570
71. Rashid S., Watanabe T., Sakaue T., and Lewis G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36 (2003) 421-429
72. Rashid S., Uffelman K.D., and Lewis G.F. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 16 (2002) 24-28
73. Lewis G.F., Rashid S., Uffelman K.D., and Lamarche B. Mechanism of HDL lowering in insulin resistant states. Adv Exp Med Biol 498 (2001) 273-277
74. Shafrir E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 8 (1992) 179-208
75. Shafrir E., Ziv E., and Mosthaf L. Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci 892 (1999) 223-246
76. Collier G., Walder K., De Silva A., et al. New approaches to gene discovery with animal models of obesity and diabetes. Ann N Y Acad Sci 967 (2002) 403-413
77. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 106 (2000) 459-465
78. Kozak L.P., and Rossmeisl M. Adiposity and the development of diabetes in mouse genetic models. Ann N Y Acad Sci 967 (2002) 80-87
79. Shafrir E., and Ziv E. Cellular mechanism of nutritionally induced insulin resistance: the desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome. J Basic Clin Physiol Pharmacol 9 (1998) 347-385
80. Silver D.L., Jiang X.C., Arai T., Bruce C., and Tall A.R. Receptors and lipid transfer proteins in HDL metabolism. Ann N Y Acad Sci 902 (2000) 103-111
81. Park J., Rho H.K., Kim K.H., Choe S.S., Lee Y.S., and Kim J.B. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol 25 (2005) 5146-5157
82. Wiegman C.H., Bandsma R.H., Ouwens M., et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52 (2003) 1081-1089
83. Muurling M., Mensink R.P., Pijl H., Romijn J.A., Havekes L.M., and Voshol P.J. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism 52 (2003) 1078-1083
84. Matsusue K., Haluzik M., Lambert G., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111 (2003) 737-747
85. Siri P., Candela N., Zhang Y.L., et al. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J Biol Chem 276 (2001) 46064-46072
86. Barnett M., Collier G.R., Collier F.M., Zimmet P., and O'Dea K. A cross-sectional and short-term longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia 37 (1994) 671-676
87. Collier G.R., Walder K., Lewandowski P., Sanigorski A., and Zimmet P. Leptin and the development of obesity and diabetes in Psammomys obesus. Obes Res 5 (1997) 455-458
88. Habito R.C., Barnett M., Yamamoto A., et al. Basal glucose turnover in Psammomys obesus. An animal model of type 2 (non-insulin-dependent) diabetes mellitus. Acta Diabetol 32 (1995) 187-192
89. Walder K.R., Fahey R.P., Morton G.J., Zimmet P.Z., and Collier G.R. Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). Int J Exp Diabetes Res 1 (2000) 177-184
90. Kanety H., Moshe S., Shafrir E., Lunenfeld B., and Karasik A. Hyperinsulinemia induces a reversible impairment in insulin receptor function leading to diabetes in the sand rat model of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 91 (1994) 1853-1857
91. Ziv E., Kalman R., Hershkop K., Barash V., Shafrir E., and Bar-On H. Insulin resistance in the NIDDM model Psammomys obesus in the normoglycaemic, normoinsulinaemic state. Diabetologia 39 (1996) 1269-1275
92. Walder K., Lewandowski P., Morton G., et al. Leptin resistance in a polygenic, hyperleptinemic animal model of obesity and NIDDM: Psammomys obesus. Int J Obes Relat Metab Disord 23 (1999) 83-89
93. Zoltowska M., Ziv E., Delvin E., et al. Circulating lipoproteins and hepatic sterol metabolism in Psammomys obesus prone to obesity, hyperglycemia and hyperinsulinemia. Atherosclerosis 157 (2001) 85-96
94. Taghibiglou C., Carpentier A., Van Iderstine S.C., et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 275 (2000) 8416-8425
95. Hoang V.Q., Botham K.M., Benson G.M., et al. Bile acid synthesis in hamster hepatocytes in primary culture: sources of cholesterol and comparison with other species. Biochim Biophys Acta 1210 (1993) 73-80
96. Jackson B., Gee A.N., Martinez-Cayuela M., and Suckling K.E. The effects of feeding a saturated fat-rich diet on enzymes of cholesterol metabolism in the liver, intestine and aorta of the hamster. Biochim Biophys Acta 1045 (1990) 21-28
97. Nistor A., Bulla A., Filip D.A., and Radu A. The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis 68 (1987) 159-173
98. Sullivan M.P., Cerda J.J., Robbins F.L., Burgin C.W., and Beatty R.J. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci 43 (1993) 575-578
99. Arbeeny C.M., Meyers D.S., Bergquist K.E., and Gregg R.E. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res 33 (1992) 843-851
100. Liu G.L., Fan L.M., and Redinger R.N. The association of hepatic apoprotein and lipid metabolism in hamsters and rats. Comp Biochem Physiol A 99 (1991) 223-228
101. Mangaloglu L., Cheung R.C., Van Iderstine S.C., Taghibiglou C., Pontrelli L., and Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 51 (2002) 409-418
102. Taghibiglou C., Rudy D., Van Iderstine S.C., et al. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. J Lipid Res 41 (2000) 499-513
103. Taghibiglou C., Rashid-Kolvear F., Van Iderstine S.C., et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 277 (2002) 793-803
104. Kasuga M., Karlsson F.A., and Kahn C.R. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 215 (1982) 185-187
105. Olefsky J.M. The insulin receptor. A multifunctional protein. Diabetes 39 (1990) 1009-1016
106. Combettes-Souverain M., and Issad T. Molecular basis of insulin action. Diabetes Metab 24 (1998) 477-489
107. Fantin V.R., Sparling J.D., Slot J.W., Keller S.R., Lienhard G.E., and Lavan B.E. Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells. J Biol Chem 273 (1998) 10726-10732
108. Lavan B.E., and Lienhard G.E. The insulin-elicited 60-kDa phosphotyrosine protein in rat adipocytes is associated with phosphatidylinositol 3-kinase. J Biol Chem 268 (1993) 5921-5928
109. Ogawa W., Matozaki T., and Kasuga M. Role of binding proteins to IRS-1 in insulin signalling. Mol Cell Biochem 182 (1998) 13-22
110. White M.F. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 53 (1998) 119-138
111. Fischer E.H., Charbonneau H., and Tonks N.K. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 253 (1991) 401-406
112. Backer J.M., Myers Jr. M.G., Shoelson S.E., et al. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11 (1992) 3469-3479
113. Lavan B.E., Kuhne M.R., Garner C.W., et al. The association of insulin-elicited phosphotyrosine proteins with src homology 2 domains. J Biol Chem 267 (1992) 11631-11636
114. Lee C.H., Li W., Nishimura R., et al. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci U S A 90 (1993) 11713-11717
115. Skolnik E.Y., Lee C.H., Batzer A., et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12 (1993) 1929-1936
116. Czech M.P., and Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 274 (1999) 1865-1868
117. Virkamaki A., Ueki K., and Kahn C.R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103 (1999) 931-943
118. Bjornholm M., Kawano Y., Lehtihet M., and Zierath J.R. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46 (1997) 524-527
119. Goodyear L.J., Giorgino F., Sherman L.A., Carey J., Smith R.J., and Dohm G.L. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95 (1995) 2195-2204
120. Rondinone C.M., Wang L.M., Lonnroth P., Wesslau C., Pierce J.H., and Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 94 (1997) 4171-4175
121. Zierath J.R., Krook A., and Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem 182 (1998) 153-160
122. Caro J.F., Ittoop O., Pories W.J., et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest 78 (1986) 249-258
123. Olefsky J.M. Decreased insulin binding to adipocytes and circulating monocytes from obese subjects. J Clin Invest 57 (1976) 1165-1172
124. Caro J.F., Sinha M.K., Raju S.M., et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 79 (1987) 1330-1337
125. Anai M., Funaki M., Ogihara T., et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 47 (1998) 13-23
126. Friedman J.E., Ishizuka T., Liu S., et al. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273 (1997) E1014-E1023
127. Hayakawa T., Shiraki T., Morimoto T., Shii K., and Ikeda H. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun 223 (1996) 439-444
128. Hurrell D.G., Pedersen O., and Kahn C.R. Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology 125 (1989) 2454-2462
129. Kerouz N.J., Horsch D., Pons S., and Kahn C.R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100 (1997) 3164-3172
130. Folli F., Saad M.J., Backer J.M., and Kahn C.R. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92 (1993) 1787-1794
131. Heydrick S.J., Gautier N., Olichon-Berthe C., Van Obberghen E., and Marchand-Brustel Y. Early alteration of insulin stimulation of PI 3-kinase in muscle and adipocyte from gold thioglucose obese mice. Am J Physiol 268 (1995) E604-E612
132. Accili D., Drago J., Lee E.J., et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12 (1996) 106-109
133. Araki E., Lipes M.A., Patti M.E., et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372 (1994) 186-190
134. Bruning J.C., Winnay J., Bonner-Weir S., Taylor S.I., Accili D., and Kahn C.R. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88 (1997) 561-572
135. Joshi R.L., Lamothe B., Cordonnier N., et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 15 (1996) 1542-1547
136. Tamemoto H., Kadowaki T., Tobe K., et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372 (1994) 182-186
137. Withers D.J., Gutierrez J.S., Towery H., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 (1998) 900-904
138. Fry M.J. Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1226 (1994) 237-268
139. Srivastava A.K., and Pandey S.K. Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem 182 (1998) 135-141
140. Goldstein B.J. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor 3 (1993) 1-15
141. Hashimoto N., Zhang W.R., and Goldstein B.J. Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. Biochem J 284 Pt 2 (1992) 569-576
142. Lammers R., Bossenmaier B., Cool D.E., et al. Differential activities of protein tyrosine phosphatases in intact cells. J Biol Chem 268 (1993) 22456-22462
143. Tonks N.K., Diltz C.D., and Fischer E.H. Characterization of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem 263 (1988) 6731-6737
144. Chen H., Wertheimer S.J., Lin C.H., et al. Protein-tyrosine phosphatases PTP1B and syp are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J Biol Chem 272 (1997) 8026-8031
145. Maegawa H., Ide R., Hasegawa M., et al. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J Biol Chem 270 (1995) 7724-7730
146. Elchebly M., Payette P., Michaliszyn E., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283 (1999) 1544-1548
147. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13 (2002) 51-59
148. Cheng A., Uetani N., Simoncic P.D., et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2 (2002) 497-503
149. Kaszubska W., Falls H.D., Schaefer V.G., et al. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol Cell Endocrinol 195 (2002) 109-118
150. Myers M.P., Andersen J.N., Cheng A., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 276 (2001) 47771-47774
151. Paz K., Hemi R., LeRoith D., et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272 (1997) 29911-29918
152. Zick Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int J Obes Relat Metab Disord 27 Suppl 3 (2003) S56-S60
153. Schernthaner G.H., and Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl 240 (2005) 30-40
154. Pessayre D., Fromenty B., and Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 16 (2004) 1095-1105
155. Fernandez-Real J.M., Broch M., Vendrell J., and Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26 (2003) 1362-1368
156. Sonnenberg G.E., Krakower G.R., and Kissebah A.H. A novel pathway to the manifestations of metabolic syndrome. Obes Res 12 (2004) 180-186
157. Shibasaki M., Takahashi K., Itou T., Bujo H., and Saito Y. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun 309 (2003) 419-424
158. Bastard J.P. Insulin resistance and adipose tissue gene expression in humans. Ann Biol Clin (Paris) 62 (2004) 25-31
159. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311 (2003) 372-379
160. Devaraj S., Venugopal S.K., Singh U., and Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes 54 (2005) 85-91
161. Yu Y.H., and Ginsberg H.N. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 96 (2005) 1042-1052
162. Manco M., Calvani M., and Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab 6 (2004) 402-413
163. Smith A.G., and Muscat G.E. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. Int J Biochem Cell Biol 37 (2005) 2047-2063
164. Watt M.J., Holmes A.G., Steinberg G.R., Mesa J.L., Kemp B.E., and Febbraio M.A. Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. Am J Physiol Endocrinol Metab 287 (2004) E120-E127
165. Soni K.G., Lehner R., Metalnikov P., et al. Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase. J Biol Chem 279 (2004) 40683-40689
166. Zimmermann R., Strauss J.G., Haemmerle G., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306 (2004) 1383-1386
167. Kern P.A., Mandic A., and Eckel R.H. Regulation of lipoprotein lipase by glucose in primary cultures of isolated human adipocytes. Relevance to hypertriglyceridemia of diabetes. Diabetes 36 (1987) 1238-1245
168. Ong J.M., and Kern P.A. The role of glucose and glycosylation in the regulation of lipoprotein lipase synthesis and secretion in rat adipocytes. J Biol Chem 264 (1989) 3177-3182
169. Picard F., Naimi N., Richard D., and Deshaies Y. Response of adipose tissue lipoprotein lipase to the cephalic phase of insulin secretion. Diabetes 48 (1999) 452-459
170. Goldberg I.J., and Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 6 (2001) D388-D405
171. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 3 (1998) d169-d175
172. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 18 Suppl 2 (2002) S5-S9
173. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 (1999) 253-259
174. Shulman G.I. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 84 (1999) 3J-10J
175. Hazel M., Cooksey R.C., Jones D., et al. Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 145 (2004) 2118-2128
176. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
177. Koteish A., and Diehl A.M. Animal models of steatosis. Semin Liver Dis 21 (2001) 89-104
178. Faraj M., Lu H.L., and Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol 82 (2004) 170-190
179. Frayn K.N. Obesity and metabolic disease: is adipose tissue the culprit?. Proc Nutr Soc 64 (2005) 7-13
180. Ballantyne G.H., Gumbs A., and Modlin I.M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 15 (2005) 692-699
181. Merl V., Peters A., Oltmanns K.M., et al. Serum adiponectin concentrations during a 72-hour fast in over- and normal-weight humans. Int J Obes Relat Metab Disord 29 (2005) 998-1001
182. Singhal A., Jamieson N., Fewtrell M., Deanfield J., Lucas A., and Sattar N. Adiponectin predicts insulin resistance but not endothelial function in young healthy adolescents. J Clin Endocrinol Metab 90 (2005) 4615-4621
183. Jan V., Cervera P., Maachi M., et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 9 (2004) 555-564
184. Kopp H.P., Krzyzanowska K., Mohlig M., Spranger J., Pfeiffer A.F., and Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes Relat Metab Disord 29 (2005) 766-771
185. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27 (2004) 2450-2457
186. Reinehr T., Roth C., Menke T., and Andler W. Adiponectin before and after weight loss in obese children. J Clin Endocrinol Metab 89 (2004) 3790-3794
187. Asensio C., Cettour-Rose P., Theander-Carrillo C., Rohner-Jeanrenaud F., and Muzzin P. Changes in glycemia by leptin administration or high-fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. Endocrinology 145 (2004) 2206-2213
188. Jung H.S., Youn B.S., Cho Y.M., et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54 (2005) 314-320
189. Rajala M.W., Qi Y., Patel H.R., et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53 (2004) 1671-1679
190. Vozarova de Court, Degawa-Yamauchi M., Considine R.V., and Tataranni P.A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53 (2004) 1279-1284
191. Richardson M.C., Cameron I.T., Simonis C.D., et al. Insulin and human chorionic gonadotropin cause a shift in the balance of sterol regulatory element-binding protein (SREBP) isoforms toward the SREBP-1c isoform in cultures of human granulosa cells. J Clin Endocrinol Metab 90 (2005) 3738-3746
192. Weber L.W., Boll M., and Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J Gastroenterol 10 (2004) 3081-3087
193. Eberle D., Hegarty B., Bossard P., Ferre P., and Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86 (2004) 839-848
194. Hegarty B.D., Bobard A., Hainault I., Ferre P., Bossard P., and Foufelle F. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc Natl Acad Sci U S A 102 (2005) 791-796
195. Toth J.I., Datta S., Athanikar J.N., Freedman L.P., and Osborne T.F. Selective coactivator interactions in gene activation by SREBP-1a and -1c. Mol Cell Biol 24 (2004) 8288-8300
196. Hitoshi S. Lipid synthetic transcription factor, SREBP. Nippon Rinsho 63 (2005) 897-907
197. Kotzka J., Lehr S., Roth G., Avci H., Knebel B., and Muller-Wieland D. Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding Protein-2 at serine residues 432 and 455 in vivo. J Biol Chem 279 (2004) 22404-22411
198. Roth G., Kotzka J., Kremer L., et al. MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J Biol Chem 275 (2000) 33302-33307
199. Takahashi A., Shimano H., Nakagawa Y., et al. Transgenic mice overexpressing SREBP-1a under the control of the PEPCK promoter exhibit insulin resistance, but not diabetes. Biochim Biophys Acta 1740 (2005) 427-433
200. Datta S., and Osborne T.F. Activation domains from both monomers contribute to transcriptional stimulation by sterol regulatory element-binding protein dimers. J Biol Chem 280 (2005) 3338-3345
201. Guillet-Deniau I., Pichard A.L., Kone A., et al. Glucose induces de novo lipogenesis in rat muscle satellite cells through a sterol-regulatory-element-binding-protein-1c-dependent pathway. J Cell Sci 117 (2004) 1937-1944
202. Miyazaki M., Dobrzyn A., Man W.C., et al. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem 279 (2004) 25164-25171
203. Shimizu S., Ugi S., Maegawa H., et al. Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J Biol Chem 278 (2003) 43095-43101
204. Nagai Y., Nishio Y., Nakamura T., Maegawa H., Kikkawa R., and Kashiwagi A. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Am J Physiol Endocrinol Metab 282 (2002) E1180-E1190
205. Sass D.A., Chang P., and Chopra K.B. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 50 (2005) 171-180
206. McClain C.J., Mokshagundam S.P., Barve S.S., et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol 34 (2004) 67-79
207. Ratziu V., Tahiri M., and Bonyhay L. Nonalcoholic steatohepatitis. Ann Endocrinol (Paris) 66 (2005) 1S71-1S80
208. Bahrami H., Daryani N.E., Mirmomen S., Kamangar F., Haghpanah B., and Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol 3 (2003) 27
209. Loguercio C., De Simone T., D'Auria M.V., et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36 (2004) 398-405
210. Tagle A.M. Non-alcoholic fatty liver. Rev Gastroenterol Peru 23 (2003) 49-57
211. Bugianesi E., Gastaldelli A., Vanni E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005) 634-642
212. Abrams J.J., Ginsberg H., and Grundy S.M. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31 (1982) 903-910
213. Dunn F.L., Grundy S.M., Bilheimer D.W., Havel R.J., and Raskin P. Impaired catabolism of very low-density lipoprotein-triglyceride in a family with primary hypertriglyceridemia. Metabolism 34 (1985) 316-324
214. Howard B.V., Abbott W.G., Beltz W.F., et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism 36 (1987) 870-877
215. Sparks J.D., and Sparks C.E. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1215 (1994) 9-32
216. Hauner H. Insulin resistance and the metabolic syndrome-a challenge of the new millennium. Eur J Clin Nutr 56 Suppl 1 (2002) S25-S29
217. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28 (1987) 613-628
218. Reaven G.M., and Chen Y.D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4 (1988) 639-652
219. Fisher E.A., and Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277 (2002) 17377-17380
220. Sniderman A.D., and Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13 (1993) 629-636
221. Yao Z., and McLeod R.S. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim Biophys Acta 1212 (1994) 152-166
222. Yao Z., Tran K., and McLeod R.S. Intracellular degradation of newly synthesized apolipoprotein B. J Lipid Res 38 (1997) 1937-1953
223. Gordon D.A., and Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 1486 (2000) 72-83
224. Adeli K., and Theriault A. Insulin modulation of human apolipoprotein B mRNA translation: studies in an in vitro cell-free system from HepG2 cells. Biochem Cell Biol 70 (1992) 1301-1312
225. Au W.S., Kung H.F., and Lin M.C. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38. Diabetes 52 (2003) 1073-1080
226. Phung T.L., Roncone A., Jensen K.L., Sparks C.E., and Sparks J.D. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem 272 (1997) 30693-30702
227. Brown A.M., and Gibbons G.F. Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol 21 (2001) 1656-1661
228. Gibbons G.F., Bartlett S.M., Sparks C.E., and Sparks J.D. Extracellular fatty acids are not utilized directly for the synthesis of very-low-density lipoprotein in primary cultures of rat hepatocytes. Biochem J 287 Pt 3 (1992) 749-753
229. Bostrom K., Boren J., Wettesten M., et al. Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem 263 (1988) 4434-4442
230. Dixon J.L., Furukawa S., and Ginsberg H.N. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 266 (1991) 5080-5086
231. Pullinger C.R., North J.D., Teng B.B., Rifici V.A., Ronhild de Brito A.E., and Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res 30 (1989) 1065-1077
232. Cartwright I.J., and Higgins J.A. Intracellular degradation in the regulation of secretion of apolipoprotein B-100 by rabbit hepatocytes. Biochem J 314 Pt 3 (1996) 977-984
233. White A.L., Graham D.L., LeGros J., Pease R.J., and Scott J. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells. A function of the ability of apolipoprotein B to direct lipoprotein assembly and escape presecretory degradation. J Biol Chem 267 (1992) 15657-15664
234. Zhang Z., Cianflone K., and Sniderman A.D. Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship. Arterioscler Thromb Vasc Biol 19 (1999) 743-752
235. Patsch W., Tamai T., and Schonfeld G. Effect of fatty acids on lipid and apoprotein secretion and association in hepatocyte cultures. J Clin Invest 72 (1983) 371-378
236. Sparks J.D., Collins H.L., Sabio I., et al. Effects of fatty acids on apolipoprotein B secretion by McArdle RH-7777 rat hepatoma cells. Biochim Biophys Acta 1347 (1997) 51-61
237. Lin Y., Smit M.J., Havinga R., Verkade H.J., Vonk R.J., and Kuipers F. Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes. Biochim Biophys Acta 1256 (1995) 88-96
238. Liang J.S., Distler O., Cooper D.A., et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7 (2001) 1327-1331
239. Battula S.B., Fitzsimons O., Moreno S., et al. Postprandial apolipoprotein B48- and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?. Metabolism 49 (2000) 1049-1054
240. Chen Y.D., Swami S., Skowronski R., Coulston A., and Reaven G.M. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76 (1993) 172-177
241. Emken E.A., Rohwedder W.K., Adlof R.O., DeJarlais W.J., and Gulley R.M. Absorption and distribution of deuterium-labeled trans- and cis-11-octadecenoic acid in human plasma and lipoprotein lipids. Lipids 21 (1986) 589-595
242. Gangl A., and Ockner R.K. Intestinal metabolism of plasma free fatty acids. Intracellular compartmentation and mechanisms of control. J Clin Invest 55 (1975) 803-813
243. Lewis G.F., O'Meara N.M., Soltys P.A., et al. Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab 71 (1990) 1041-1050
244. Lewis G.F., O'Meara N.M., Soltys P.A., et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72 (1991) 934-944
245. O'Meara N.M., Lewis G.F., Cabana V.G., Iverius P.H., Getz G.S., and Polonsky K.S. Role of basal triglyceride and high density lipoprotein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab 75 (1992) 465-471
246. Boquist S., Ruotolo G., Tang R., et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 100 (1999) 723-728
247. Doi H., Kugiyama K., Oka H., et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102 (2000) 670-676
248. Karpe F., Boquist S., Tang R., Bond G.M., de Faire U., and Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42 (2001) 17-21
249. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154 (2001) 229-236
250. Yu K.C., and Cooper A.D. Postprandial lipoproteins and atherosclerosis. Front Biosci 6 (2001) D332-D354
251. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003) 733-749
252. Guo Q., Avramoglu R.K., and Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 54 (2005) 689-697